Hair changes during GLP-1 treatment

A GLP-1 medication can be helping your health while hair begins shedding or looks thinner. The timing deserves attention alongside appetite, intake, weight change and the scalp findings.

Hair loss has been reported during treatment with semaglutide and tirzepatide. Reports include shedding and pattern thinning. Establishing the type of loss helps identify what needs addressing.^1,2

Build a dated history

Record when treatment began, dose changes and the first noticeable hair change. Include the rate of weight change, illness and periods when eating became difficult.

Older photographs can establish whether gradual thinning was already present. A new prescription is an important clue, while the scalp still needs its own examination.

This helps separate events that occurred together from those that preceded the hair change by several months.

Reduced appetite can make adequate intake difficult

Some people lose their usual cues to eat. The nutritional review needs the food actually consumed, including total energy, protein and variety.

At the American Hair Research Society discussion I attended, clinicians described encouraging regular eating, adequate protein and reminders when appetite was low. Supplements were also discussed for nutritional support. These clinical observations are helping shape questions for further research.

A practical recommendation should address the person's actual intake, barriers to eating and any identified shortfalls. Relevant tests can answer selected questions alongside the eating history.

The food record and medication record can explain different parts of the same change.

Include fasting without imposing a cutoff

Long gaps between meals may be intentional or result from reduced appetite. Record them alongside changes in intake and weight.

Research is examining how fasting changes the energy available to follicles and surrounding fat. Experimental work and a small human study raise useful questions, but do not establish a fasting-hour threshold that predicts individual hair loss.³

Interpret dose observations carefully

Clinicians at the AHRS discussion described hair changes after some dose increases. Appetite suppression, intake and weight can also change at that point.

Zepbound trial data report hair loss, but rates across doses do not show a steady dose-related increase.² A suspected medication effect deserves review with the prescriber in the context of these other findings.

Keep the hair diagnosis specific

A Johns Hopkins pilot study is testing tirzepatide for active central centrifugal cicatricial alopecia. The registered plan includes 20 adults and no separate comparison group. Its treatment benefit remains under study.⁴

That disease-specific question differs from shedding during weight management. Bring the timeline, food history and older images. The next recommendation can address nutrition, the hair condition and any medication review while supporting the wider medical treatment.